While many currently used glycomedicines are composed of naturally derived glycans, important advances in carbohydrate chemistry have enabled the development of chemically defined conjugated constructs against a number of pathogens and infectious diseases. CD BioGlyco provides customized services for synthetic carbohydrate-based glycomedicine development.
A major obstacle in glycobiology and glycomedicine is the lack of pure and structurally well-defined carbohydrates and glycoconjugates. These compounds are often found in low concentrations and in microheterogeneous forms, greatly complicating their isolation and characterization. In many cases, well-defined carbohydrates can only be obtained by chemical- or enzymatic synthesis and such compounds are increasingly used to address important problems in glycobiology research and for vaccine and drug discovery.
Since chemical or enzymatic synthesis is a powerful method not only for the construction of natural polysaccharides, but also for the design of non-natural polysaccharide analogues having tailored biological functions. It is a promising strategy for creating bioactive polysaccharides and their analogues by utilizing polysaccharides found in nature.
Fig.1 Structures of the Brucella O-antigen and their synthetic oligosaccharides and glycoconjugates (Mettu, et al., 2020)
Enzymatic and chemical modifications are commonly used in the development of synthetic carbohydrate-based glycomedicines. CD BioGlyco has established an advanced carbohydrate-based glycomedicine development platform and a variety of methods to meet the special needs of customers. Our methods include but are not limited to:
CD BioGlyco offers advanced customization services for the development of synthetic carbohydrate-based glycomedicines such as anti-inflammatory drugs. If you are interested in our services, please contact us for further consultation.